Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Dr Reddys Laboratories Ltd

| Quarterly Financial Results Q3 FY 2025–26

NEUTRAL SENTIMENT

Report Source

⬤21st Jan 26

Summary : Dr. Reddy's Q3FY26 saw revenue growth driven by branded businesses and favorable forex, despite Lenalidomide sales decline and regulatory challenges.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Q3FY26 Gross Margin was 53.6% (505 bps YoY and 104 bps QoQ decline), impacted by lower Lenalidomide sales, price erosion, adverse product mix, and a one-time Labour Codes provision.
  2. SG&A expenses for Q3FY26 increased 12% YoY to ₹26,918 Mn (30.8% of revenues).
  3. R&D expenses for Q3FY26 decreased 8% YoY to ₹6,149 Mn (7.0% of revenues), due to reduced development spends in Biosimilars.
  4. Q3FY26 EBITDA was ₹20,493 Mn (23.5% of revenues), declining 11% YoY.
  5. Q3FY26 Profit before Tax was ₹15,429 Mn (17.7% of revenues), declining 18% YoY.
  6. Q3FY26 Profit after Tax attributable to Equity Holders was ₹12,098 Mn (13.9% of revenues), declining 14% YoY.
  7. Q3FY26 consolidated revenues were ₹87,268 Mn (4.4% YoY growth, 0.9% QoQ decline).
  8. 9MFY26 consolidated revenues were ₹260,771 Mn (8.4% YoY growth).
  9. Global Generics segment revenue for Q3FY26 was ₹79,113 Mn (7% YoY growth), and PSAI was ₹8,018 Mn (2% YoY decline).
  10. North America generics revenue declined by 12% YoY in Q3FY26 due to lower Lenalidomide sales and price erosion.
  11. Europe revenue grew 20% YoY in Q3FY26, and Emerging Markets grew 32% YoY.
  12. Free Cash Flow for Q3FY26 was ₹3.7 billion.
  13. Net cash generated from operating activities for Q3FY26 was ₹13,975 Mn, with investments in Property, Plant & Equipment of ₹7,168 Mn.
  14. Potential government or regulatory enforcement actions and civil/criminal sanctions related to an improper payments complaint, with outcomes not reasonably ascertainable.
  15. Potential further tax liability from a foreign subsidiary audit, though deemed not probable.
  16. Uncertainties relating to geo-political conflicts, with the company expecting full recovery of assets.
  17. As of December 31, 2025, Cash and Cash Equivalents and Other Investments were ₹87,191 Mn, Trade Receivables ₹103,206 Mn, and Inventories ₹79,009 Mn.
  18. Property, Plant, and Equipment stood at ₹115,544 Mn, and Goodwill and Other Intangible Assets at ₹114,727 Mn.
  19. Loans and Borrowings were ₹67,732 Mn, and Equity was ₹375,756 Mn.
  20. Operating Working Capital was ₹141.4 billion, Net Cash Surplus ₹30.7 billion, and Net Debt to Equity was (0.08).
  21. The report presents both unaudited consolidated financial results (prepared in accordance with IFRS) and unaudited standalone financial results (prepared in accordance with Indian Accounting Standards).

Corporate Overview

  1. Major markets include USA, India, Russia & CIS countries, China, Brazil, and Europe.
  2. Specific mentions of North America, Germany, UK, and Emerging Markets.
  3. Lower Lenalidomide sales and higher price erosion in North America generics.
  4. Pricing pressure in Europe generics and lower volume uptake in API business.
  5. Technical challenges led to discontinuance of conjugated estrogen development.
  6. USFDA CRLs for denosumab and rituximab biosimilars due to manufacturing facility observations.
  7. Ongoing anonymous complaint regarding improper payments and geo-political conflicts uncertainties.
  8. Global pharmaceutical company offering APIs, generics, branded generics, biosimilars, and OTC products.
  9. Focuses on therapeutic areas like gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
  10. Co-Chairman & MD G V Prasad noted Q3FY26 growth from branded businesses and favorable forex, offsetting lower Lenalidomide sales.
  11. Focus remains on disciplined execution of strategic priorities: base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities to create long-term stakeholder value.
  12. Global Generics (including Biologics business)
  13. Pharmaceutical Services and Active Ingredients (PSAI)
  14. Others
  15. Manufacturing facilities and development facilities are deployed interchangeably across segments.
  16. Capital expenditure for Q3FY26 was ₹6.7 billion.

Risk Factors

  1. Lower Lenalidomide sales, price erosion.
  2. USFDA biosimilar manufacturing facility observations.
  3. Improper payments complaint, regulatory scrutiny.
  4. Product development technical challenges.

Key Drivers

  1. Strategic oncology drug collaboration.
  2. Launched novel Hepatitis-E vaccine.
  3. Semaglutide injection marketing authorization.
  4. European denosumab biosimilar approval.

Auditor’s Report

  1. The auditors issued an unmodified review report on both the unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025.

Board Commentary

  1. Impact of new Labour Codes on employee benefits.
  2. Discontinuance of conjugated estrogen development due to technical challenges.
  3. Potential tax liabilities from a foreign subsidiary audit.
  4. Impairment of intangibles due to procurement constraints and adverse market conditions.
  5. Risks from an anonymous complaint regarding improper payments, potentially leading to regulatory enforcement actions.
  6. Uncertainties from geo-political conflicts affecting asset recoverability.
  7. USFDA Complete Response Letters (CRLs) for biosimilars due to manufacturing facility observations.
  8. New Labour Codes effective from November 21, 2025, impacting employee benefits.
  9. Field Tax Audit Report for a foreign subsidiary classified certain services as subject to VAT.
  10. Amendment in The Finance Act 2024 led to a write-off of Deferred Tax Asset.
  11. Anonymous complaint regarding improper payments in Ukraine and other countries, violating U.S. anti-corruption laws, with ongoing engagement with SEC and DOJ.
  12. USFDA Notice of Non-Compliance for Semaglutide injection in Canada.
  13. USFDA CRLs for denosumab and rituximab biosimilars due to manufacturing facility observations.
  14. Capital expenditure for Q3FY26 was ₹6.7 billion.

Corporate Governance

  1. The company has a Global Compliance Framework and has undertaken enhancement initiatives.
  2. An investigation into an anonymous complaint was conducted at the instruction of a committee of the Company's Board of Directors.
  3. The Audit Committee reviewed and recommended the unaudited consolidated and standalone financial results to the Board of Directors.
  4. An anonymous complaint was received alleging improper payments to healthcare professionals in Ukraine and potentially other countries, in violation of U.S. anti-corruption laws (FCPA).
  5. The matter was disclosed to the U.S. Department of Justice (DOJ), Securities and Exchange Commission (SEC), and Securities Exchange Board of India.

Management Discussion & Analysis

Future Strategy

  1. Strategic priorities include base business growth, pipeline advancement, operational efficiencies, and pursuing select inorganic opportunities.
  2. R&D efforts are focused on complex generics, biosimilars, peptides, and novel biologics.

Industry Overview

  1. New Labour Codes in India, effective November 21, 2025, introduce changes impacting employee benefits, including gratuity and leave encashment.

Macroeconomic Outlook

  1. Uncertainties related to geo-political conflicts (including Russia and Ukraine) are being monitored for their impact on asset recoverability.

Operational Focus Areas

  1. Disciplined execution of strategic priorities.
  2. Monitoring implications of new Labour Codes.
  3. Closely monitoring geo-political conflicts for asset recoverability.

Performance Drivers

  1. Growth was driven by continued momentum in branded businesses, favorable foreign exchange movements, new product launches, price increases, and higher volumes across key markets.

Risk Control Measures

  1. Assessed implications of new Labour Codes and recognized incremental costs.
  2. Filed objections to tax audit report and recorded a provision.
  3. Expects full recovery of assets despite geo-political conflicts.
  4. Submitted responses to USFDA observations for rituximab biosimilar.

Critical Risks

  1. Impact of new Labour Codes on employee benefits.
  2. Discontinuance of conjugated estrogen development due to technical challenges.
  3. Potential tax liabilities from a foreign subsidiary audit.
  4. Impairment of intangibles due to procurement constraints and adverse market conditions.
  5. Risks from an anonymous complaint regarding improper payments, potentially leading to regulatory enforcement actions.
  6. Uncertainties from geo-political conflicts affecting asset recoverability.
  7. USFDA Complete Response Letters (CRLs) for biosimilars due to manufacturing facility observations.
Dr Reddys Laboratories Ltd (DRREDDY) Quarterly Report Analysis & Insights | Dhanarthi